<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03031301</url>
  </required_header>
  <id_info>
    <org_study_id>240CLD</org_study_id>
    <nct_id>NCT03031301</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy and Safety of the Vibrant Capsule Administered 5 Times Per Week</brief_title>
  <official_title>A Prospective, Multicenter, Randomized, Double-blind, Sham-controlled Study to Assess the Efficacy and Safety of the Vibrant Capsule Administered 5 Times Per Week</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vibrant Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vibrant Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective, adaptive, multicenter, randomized, double-blind, Sham-controlled&#xD;
      study, to evaluate the efficacy and safety of the Vibrant Capsule in relieving constipation&#xD;
      in subjects with functional constipation.&#xD;
&#xD;
      Two arms will be assessed:&#xD;
&#xD;
        -  Vibrant Capsule administered 5 times per week&#xD;
&#xD;
        -  Sham Capsule administered 5 times per week&#xD;
&#xD;
      Subjects will follow a 2 weeks baseline period and then take the Vibrant Capsule for a&#xD;
      treatment period of 8 weeks.&#xD;
&#xD;
      Data reporting will be done on an electronic Case Report Form (eCRF) and an eDiary.&#xD;
&#xD;
      Subjects will be asked to refrain from taking any medication or supplement to relieve their&#xD;
      constipation, during the entire study period.&#xD;
&#xD;
      After the 14 days of run-in period, the subjects will return and eligibility will be&#xD;
      re-assessed. Subjects will be trained on how to use the base unit and will swallow the first&#xD;
      capsule on site the day of baseline visit. They will activate and ingest the rest of the&#xD;
      capsules at home by themselves, using the base unit.&#xD;
&#xD;
      Subjects will be instructed to complete a simple subject eDiary each day throughout the&#xD;
      duration of the study. A final visit will take place at the end of the 8 week treatment&#xD;
      period.&#xD;
&#xD;
      Subjects will receive phone calls at least once a week and subject compliance will be&#xD;
      monitored during the 8 weeks of the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Spontaneous Bowel Movement (CSBM) success rate, defined as an increase from the run-in period of at least two weekly Complete Spontaneous Bowel Movement (CSBM) during at least 6 of the 8 weeks of treatment.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Complete Spontaneous Bowel Movements</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Constipation</condition>
  <arm_group>
    <arm_group_label>Vibrant capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive the Vibrant capsule 5 times a week for 8 weeks of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham capsule</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients will receive the sham capsule (activated, non-vibrating) 5 times a week for 8 weeks of treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vibrant capsule</intervention_name>
    <description>One Vibrant capsule will be ingested 5 times per week for 8 weeks of treatment.</description>
    <arm_group_label>Vibrant capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham capsule</intervention_name>
    <description>One Sham capsule will be ingested 5 times per week for 8 weeks of treatment.</description>
    <arm_group_label>Sham capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects aged 22 years and older&#xD;
&#xD;
          2. Subjects with Chronic Idiopathic Constipation (CIC) according to Rome III criteria and&#xD;
             who have not experienced relief of their symptoms from available therapies&#xD;
&#xD;
          3. Subjects with an average of &lt;3 Spontaneous Bowel Movements (SBM) per week and â‰¥1 SBM&#xD;
             per week&#xD;
&#xD;
          4. Normal colonoscopy performed within 10 years prior to study participation, unless the&#xD;
             subjects are &lt;50 years old and without alarm signs and/or symptoms&#xD;
&#xD;
          5. Subject signed the Informed Consent Form (ICF)&#xD;
&#xD;
          6. Female subjects must have a negative pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of complicated/obstructive diverticular disease&#xD;
&#xD;
          2. History of intestinal or colonic obstruction, or suspected intestinal obstruction.&#xD;
&#xD;
          3. History of significant gastrointestinal disorder, including any form of inflammatory&#xD;
             bowel disease or gastrointestinal malignancy (celiac disease is accepted if the&#xD;
             subject has been treated and is in remission)&#xD;
&#xD;
          4. History of gastroparesis&#xD;
&#xD;
          5. Use of any of the following medications:&#xD;
&#xD;
               -  Medications that may affect intestinal motility, prokinetics, anti-depressants,&#xD;
                  anti-Parkinsonian medications, opiates, opioids, calcium-channel blockers,&#xD;
                  aluminum/magnesium hydroxide&#xD;
&#xD;
               -  With the exception of antidepressants, thyroid or hormonal replacement therapy,&#xD;
                  when the subject has been on a stable dose for at least 3 months prior to&#xD;
                  enrollment.&#xD;
&#xD;
          6. Clinical evidence of significant respiratory, cardiovascular, renal, hepatic, biliary,&#xD;
             endocrine, psychiatric or neurologic disease.&#xD;
&#xD;
          7. Presence of cardiac pacemaker or gastric electrical stimulator.&#xD;
&#xD;
          8. History of, or current eating disorders, such as anorexia, bulimia, or compulsory&#xD;
             overeating.&#xD;
&#xD;
          9. Diagnosis of mega-rectum or colon, congenital anorectal malformation, clinically&#xD;
             significant rectocele, history of intestinal resection (with an exception for&#xD;
             appendectomy, cholecystectomy and inguinal hernia repair), history of bariatric&#xD;
             surgery or evidence of any structural abnormality of the gastrointestinal tract that&#xD;
             might affect transit&#xD;
&#xD;
         10. History of Zenker's diverticulum, dysphagia, Barrett's esophagus, esophageal stricture&#xD;
             or achalasia&#xD;
&#xD;
         11. Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs)&#xD;
&#xD;
         12. Subjects with pelvic floor dysfunction/defecatory disorder&#xD;
&#xD;
         13. Participation in another clinical study within one month prior to screening.&#xD;
&#xD;
         14. Women who are pregnant or lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dvora Darky</last_name>
    <phone>+972-4-6660885</phone>
    <email>dvora.d@vibrantgastro.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lior Ben Tsur</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Avant Guntersville</name>
      <address>
        <city>Guntersville</city>
        <state>Alabama</state>
        <zip>35976</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Abath</last_name>
    </contact>
    <investigator>
      <last_name>William A Nixon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Floridian Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33145</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milene Garcia</last_name>
    </contact>
    <investigator>
      <last_name>Jorge Loredo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>January 16, 2017</study_first_submitted>
  <study_first_submitted_qc>January 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2017</study_first_posted>
  <last_update_submitted>January 11, 2018</last_update_submitted>
  <last_update_submitted_qc>January 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

